Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study.
Manz K, Bahr J, Ittermann T, Döhner K, Koschmieder S, Brümmendorf TH, Griesshammer M, Nauck M, Völzke H, Heidel FH. Manz K, et al. Among authors: heidel fh. Leukemia. 2023 Aug;37(8):1745-1749. doi: 10.1038/s41375-023-01943-8. Epub 2023 Jun 23. Leukemia. 2023. PMID: 37353711 Free PMC article. No abstract available.
Pomalidomide combinations are a safe and effective option after daratumumab failure.
Brioli A, Gengenbach L, Mancuso K, Binder M, Ernst T, Heidel FH, Stauch T, Zamagni E, Hilgendorf I, Hochhaus A, Engelhardt M, von Lilienfeld-Toal M. Brioli A, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2023 Aug;149(9):6569-6574. doi: 10.1007/s00432-023-04637-x. Epub 2023 Feb 13. J Cancer Res Clin Oncol. 2023. PMID: 36781500 Free PMC article.
Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project.
Verstovsek S, Krečak I, Heidel FH, De Stefano V, Bryan K, Zuurman MW, Zaiac M, Morelli M, Smyth A, Redondo S, Bigan E, Ruhl M, Meier C, Beffy M, Kiladjian JJ. Verstovsek S, et al. Among authors: heidel fh. Biomedicines. 2023 Jul 7;11(7):1925. doi: 10.3390/biomedicines11071925. Biomedicines. 2023. PMID: 37509564 Free PMC article.
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
Wolleschak D, Mack TS, Perner F, Frey S, Schnöder TM, Wagner MC, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH. Wolleschak D, et al. Among authors: heidel fh. Haematologica. 2014 Jun;99(6):e90-3. doi: 10.3324/haematol.2014.104331. Epub 2014 Mar 14. Haematologica. 2014. PMID: 24633870 Free PMC article. No abstract available.
Gain of function in Jak2V617F-positive T-cells.
Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D. Nishanth G, et al. Among authors: heidel fh. Leukemia. 2017 Apr;31(4):1000-1003. doi: 10.1038/leu.2017.6. Epub 2017 Jan 11. Leukemia. 2017. PMID: 28074070 No abstract available.
Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells.
Dash BP, Schnöder TM, Kathner C, Mohr J, Weinert S, Herzog C, Godavarthy PS, Zanetti C, Perner F, Braun-Dullaeus R, Hartleben B, Huber TB, Walz G, Naumann M, Ellis S, Vasioukhin V, Kähne T, Krause DS, Heidel FH. Dash BP, et al. Among authors: heidel fh. J Cancer Res Clin Oncol. 2018 Oct;144(10):1933-1944. doi: 10.1007/s00432-018-2724-3. Epub 2018 Aug 6. J Cancer Res Clin Oncol. 2018. PMID: 30083817
154 results